Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.

Dorothea HoseMartin SchrederJochen HefnerMax BittrichSophia DanhofSusanne StriflerMaria-Theresa KrauthRenate SchoderBettina GisslingerHermann EinseleHeinz GisslingerStefan Knop

Published in: Journal of cancer research and clinical oncology (2020)

Elo/pom/dex is an active and well-tolerated regimen in highly advanced MM even after pretreatment with pomalidomide.

Keyphrases

multiple myeloma
low dose
high dose
disease activity
rheumatoid arthritis
newly diagnosed
ulcerative colitis